The use of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes: A quantitative benefit-risk analysis

被引：0
|
作者：
D'Souza, Lynn [1 ]
Alkabbani, Wajd [2 ]
Gamble, John-Michael [2 ]
机构：
[1] Univ Waterloo, Sch Pharm, Waterloo, ON, Canada
[2] Univ Waterloo, Waterloo, ON, Canada
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
641
引用
收藏
页码：300 / 301
页数：2
相关论文
共 50 条
  • [31] The potential use of acarbose in the prevention of type 2 diabetes and cardiovascular disease
    Chiasson, JL
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2000, 2 (0D) : D35 - D35
  • [32] Statins for Secondary Cardiovascular Disease Prevention for Older Primary Care Patients
    Niska, Richard
    Han, Beth
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2009, 101 (07) : 705 - 710
  • [33] Do statins benefit low-risk population for primary prevention of atherosclerotic cardiovascular disease: A retrospective cohort study
    Ryou, In Sun
    Kim, Ju Young
    Park, Hwa Yeon
    Oh, Sohee
    Kim, Sehun
    Kim, Hwa Jung
    FRONTIERS IN MEDICINE, 2022, 9
  • [34] DETERMINING RISK THRESHOLDS FOR INITIATING STATINS FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A BENEFIT-HARM BALANCE MODELING STUDY
    Yebyo, H.
    Aschmann, H.
    Puhan, M.
    VALUE IN HEALTH, 2019, 22 : S564 - S564
  • [35] Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients
    Ostergaard, H. B.
    Mandrup-Poulsen, T.
    Berkelmans, G. F. N.
    van der Graaf, Y.
    Visseren, F. L. J.
    Westerink, J.
    van Petersen, R.
    Dinther, B. G. F.
    Algra, A.
    Grobbee, D. E.
    Rutten, G. Eh. M.
    de Borst, G. J.
    Kappelle, L. J.
    Leiner, T.
    Nathoe, H. M.
    DIABETES & METABOLISM, 2019, 45 (03) : 254 - 260
  • [36] Prevention of cardiovascular risk in patients with type 2 diabetes mellitus with aspirin
    Duly-Bouhanick, B
    Menard, S
    Hadjadj, S
    Soares-Barbosa, S
    Plun-Favreau, J
    Guilloteau, G
    PRESSE MEDICALE, 2001, 30 (02): : 87 - 91
  • [37] Re Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes
    Nasri, H.
    DIABETES & METABOLISM, 2013, 39 (04) : 375 - 376
  • [38] Low Use of Statins in People With Type 2 Diabetes With or Without Cardiovascular Disease: A Capture Post Hoc Analysis
    Arenas, Jose Luis
    Byram, Fahri
    Darmon, Patrice
    Davis, Timothy
    Dieuzeide, Guillermo
    Hong, Tianpei
    Kaltoft, Margit S.
    Lengyel, Csaba
    Mosenzon, Ofri
    Rhee, Nicolai A.
    Russo, Giuseppina T.
    Shirabe, Shinichiro
    Thamattoor, Usha K.
    Urbancova, Katerina
    Vencio, Sergio
    Alguwaihes, Abdullah
    CIRCULATION, 2020, 142
  • [39] Audit of statin use for primary prevention of cardiovascular disease in people with Type 1 diabetes
    Maxwell, K. L.
    Munir, A.
    DIABETIC MEDICINE, 2015, 32 : 103 - 104
  • [40] Atorvastatin - A review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus
    Croom, KF
    Plosker, GL
    DRUGS, 2005, 65 (01) : 137 - 152
12345